CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
病例报告：异基因造血干细胞移植后预防性输注供者来源 CD7 CAR-T 细胞
英文原题：Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation.
查看英文原题
Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
靶向 CD7 的嵌合抗原受体（CAR）T 细胞治疗 T 细胞急性淋巴细胞白血病/淋巴瘤（T-ALL/LBL）在部分临床试验中显示出良好疗效和安全性，但多数研究采用异基因造血干细胞移植（allo-HSCT）作为桥接治疗。本文报告一例难治性 T 淋巴母细胞淋巴瘤患者在 allo-HSCT 后接受预防性供者来源抗 CD7 CAR-T 治疗并成功；由于患者 T 淋巴细胞质量较差，无法接受自体抗 CD7 CAR-T 产品。迄今患者在 HSCT 后持续完全缓解已达 20 个月。
展开英文摘要原文
Chimeric antigen receptor T cells (CAR T) targeting CD7 for T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) showed promising efficacy and safety in some clinical trials.
However, most of them were bridged with allogeneic hematopoietic stem cell transplantation (allo-HSCT).
We described successful treatment with preventive donor-derived anti-CD7 CAR-T therapy in a case of refractory T lymphoblastic lymphoma following allo-HSCT, who could not receive autologous anti-CD7 CAR-T products due to the low-quality of T lymphocytes. To date, the patient's complete remission has persisted for 20 months after HSCT.
论文信息
- 作者
- Jiang Y、Feng D、Zhu J、Wei D、Zhao C、Liu H、Shao S、Wang C
- 单位
- Department of Hematology, Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital, Shanghai, China.China
- 文献类型
- 病例报告
- 期刊
- Frontiers in immunology2024
- 原文标识
- PubMed 38745670 · DOI 10.3389/fimmu.2024.1381308
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →